Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials (2019) Anthony L, Kulke M, Caplin M, Bergsland E, Oberg K, Pavel ME, Horsch D, et al. Conference contribution Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study (2019) Pavel ME, Borson-Chazot F, Cailleux A, Hoersch D, Lahner H, Pivonello R, Tauchmanova L, et al. Journal article Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, Caplin ME Journal article The relevance of cancer related fatigue in neuroendocrine neoplasia patients (2019) Banz S, Mellar K, Letsch A, Scheibenbogen C, Pavel ME, Grabowski P Conference contribution Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Fazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Chan DL, Yao JC, Camaghi C, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Systemic Anti-Cancer Therapies Impair the Nutritional Status of Neuroendocrine Tumor Patients (2019) Pevny S, Maasberg S, Karber M, Knappe-Drzikova B, Weylandt KH, Jann H, Pavel ME, et al. Conference contribution Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? (2019) Merola E, Rinke A, Partelli S, Gress TM, Andreasi V, Kollar A, Perren A, et al. Journal article Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE (2019) Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, Pavel ME, Prasad V Journal article Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study (2019) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Journal article, Review article